Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RYZ211/212 · 1 trial · 5 indications
To evaluate the biodistribution of RYZ211 using SUV (mean, maximum, and peak) of critical organs (blood pool, salivary glands, thyroid, pancreas, liver, kidney \[cortex\], bone) and tumors; tumor-to-normal organ tracer uptake ratios in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC
To evaluate the long biodistribution and radiation absorbed doses in critical organs and tumors, and the effective dose of RYZ212 by using calculated mean TIAC (MBq · h/MBq), radiation absorbed dose coefficients (mGy/MBq) and absorbed dose (Gy) to critical organs (salivary glands, thyroid, pancreas, liver, kidneys, bone marrow), calculated mean TIAC (MBq · h/MBq) and radiation absorbed dose coefficients (mGy/MBq) and absorbed dose (Gy) to tumors, calculated whole-body effective dose (mSv/MBq)
| Arm | Type | Description |
|---|---|---|
| RYZ211/212 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RYZ211/212 | DIAGNOSTIC_TEST | Imaging Agent |
Inclusion Criteria: * Are at least 18 years old at the time of signing the informed consent form (ICF) * Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC Exclusion Criteria: * TROP2-targeting antibody-drug conjugates (ADCs) such as sacituzumab govitecan or datopotamab...
RYZ211/212 is an investigational imaging agent being studied in metastatic urothelial carcinoma, as well as in hormone receptor positive HER2 negative breast cancer, triple-negative breast cancer, and non-small cell lung cancer. It is a TROP2 binder intended for use in imaging studies.
RYZ211/212 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting a Phase 1 clinical trial to evaluate the drug as an imaging agent in multiple cancer types.
RYZ211/212 targets TROP2, a protein commonly expressed in various solid tumors. As a TROP2 binder, it is designed to bind to this target for imaging purposes, potentially enabling visualization of tumors that express TROP2.
RYZ211/212 is in Phase 1 clinical development. The ongoing trial is an early Phase 1 study, and the drug is investigational, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials.
RYZ211/212 is being studied in a single clinical trial with the identifier NCT07671092. This early Phase 1 imaging study is enrolling 40 participants with metastatic urothelial carcinoma, breast cancer subtypes, and non-small cell lung cancer, and is being conducted in New Zealand.